Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R.

Br J Haematol. 2018 Jul;182(2):231-244. doi: 10.1111/bjh.15394. Epub 2018 Jun 25.

2.

Ninety-minute daratumumab infusion is safe in multiple myeloma.

Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, Benson DM, Rosko AE, Efebera YA, Hofmeister CC.

Leukemia. 2018 Mar 31. doi: 10.1038/s41375-018-0120-2. [Epub ahead of print] No abstract available.

PMID:
29679038
3.

Importin-β and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells.

Nuovo G, Tran H, Gutierrez A, Fadda P, Pichiorri F, Caserta E, Hofmeister CC, Chesi M, Leif Bergsagel P, Morris D, Shi Q, Coffey M, Thirukkumaran C.

Ann Diagn Pathol. 2018 Feb;32:28-34. doi: 10.1016/j.anndiagpath.2017.10.001. Epub 2017 Oct 7.

PMID:
29414394
4.

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, Baz R, Mau-Sorensen M, Berdeja JG, Savona M, Savoie L, Trudel S, Areethamsirikul N, Unger TJ, Rashal T, Hanke T, Kauffman M, Shacham S, Reece D.

Blood. 2018 Feb 22;131(8):855-863. doi: 10.1182/blood-2017-08-797886. Epub 2017 Dec 4.

PMID:
29203585
5.

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL.

Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematol. 2018 Aug;5(8):e332.

PMID:
28826616
6.

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2017 Dec;31(12):2695-2701. doi: 10.1038/leu.2017.173. Epub 2017 Jun 2.

7.

G-CSF improves safety when you start the day after autologous transplant in multiple myeloma.

Sborov DW, Cho YK, Cottini F, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, Phelps MA, Hofmeister CC.

Leuk Lymphoma. 2017 Dec;58(12):2947-2951. doi: 10.1080/10428194.2017.1318436. Epub 2017 May 16. No abstract available.

PMID:
28509594
8.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC.

Leuk Lymphoma. 2017 Oct;58(10):2310-2318. doi: 10.1080/10428194.2017.1298751. Epub 2017 Mar 7.

PMID:
28270022
9.

Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA.

Clin Pharmacol Ther. 2017 Sep;102(3):511-519. doi: 10.1002/cpt.644. Epub 2017 May 26.

PMID:
28160288
10.

Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.

Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC.

Mol Carcinog. 2017 Jul;56(7):1722-1732. doi: 10.1002/mc.22626. Epub 2017 Feb 16.

PMID:
28150872
11.

Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM.

J Exp Med. 2017 May 1;214(5):1557. doi: 10.1084/jem.2012095001172017c. Epub 2017 Jan 19. No abstract available.

12.

How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.

Hofmeister CC, Lonial S.

J Clin Oncol. 2016 Dec 20;34(36):4421-4430. Epub 2016 Oct 31. Review.

PMID:
27998219
13.

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS.

Lancet Haematol. 2017 Jan;4(1):e24-e34. doi: 10.1016/S2352-3026(16)30166-1. Epub 2016 Dec 1.

14.

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D, Jakubowiak AJ, Reich S, Trikha M, Anderson KC.

Blood. 2016 Jun 2;127(22):2693-700. doi: 10.1182/blood-2015-12-686378. Epub 2016 Mar 23.

15.

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F.

Mol Cancer Ther. 2016 May;15(5):830-41. doi: 10.1158/1535-7163.MCT-15-0240-T. Epub 2016 Jan 25.

16.

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F.

J Proteomics. 2016 Mar 16;136:89-98. doi: 10.1016/j.jprot.2015.12.016. Epub 2016 Jan 13.

17.

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.

Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F.

Oncotarget. 2015 Oct 13;6(31):31134-50. doi: 10.18632/oncotarget.5290.

18.

Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).

Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM.

Biol Blood Marrow Transplant. 2016 Jan;22(1):71-9. doi: 10.1016/j.bbmt.2015.07.034. Epub 2015 Aug 6.

19.

Tocilizumab for steroid refractory acute graft-versus-host disease.

Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA.

Leuk Lymphoma. 2016;57(1):81-5. doi: 10.3109/10428194.2015.1045896. Epub 2015 Jul 3.

20.

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.

Sborov DW, Benson DM, Williams N, Huang Y, Bowers MA, Humphries K, Efebera Y, Devine S, Hofmeister CC.

Br J Haematol. 2015 Oct;171(1):74-83. doi: 10.1111/bjh.13527. Epub 2015 Jun 8.

21.

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA.

Clin Cancer Res. 2015 Sep 15;21(18):4055-61. doi: 10.1158/1078-0432.CCR-15-0304. Epub 2015 May 21.

22.

Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome.

Chu BF, Shana'ah A, Hofmeister CC, Benson DM, Sell M, Tucker J, Pichiorri F, Efebera YA.

Eur J Case Rep Intern Med. 2014;1. pii: 2014_000093.

23.

A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.

Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC.

Clin Cancer Res. 2014 Dec 1;20(23):5946-55. doi: 10.1158/1078-0432.CCR-14-1404. Epub 2014 Oct 7.

24.

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.

Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM.

Leuk Lymphoma. 2015 Apr;56(4):1043-9. doi: 10.3109/10428194.2014.963073. Epub 2014 Nov 20.

25.

Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.

Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA.

Leuk Lymphoma. 2015 Apr;56(4):1058-65. doi: 10.3109/10428194.2014.956314. Epub 2014 Nov 20.

26.

The potential of miRNAs as biomarkers for multiple myeloma.

Rocci A, Hofmeister CC, Pichiorri F.

Expert Rev Mol Diagn. 2014 Nov;14(8):947-59. doi: 10.1586/14737159.2014.946906. Epub 2014 Aug 7. Review.

PMID:
25098410
27.

The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.

Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LA.

Bone Marrow Transplant. 2014 Oct;49(10):1323-9. doi: 10.1038/bmt.2014.155. Epub 2014 Jul 28.

28.

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK.

Br J Cancer. 2014 Jul 15;111(2):272-80. doi: 10.1038/bjc.2014.290. Epub 2014 Jun 5.

29.

Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.

Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM.

Support Care Cancer. 2014 Nov;22(11):2911-6. doi: 10.1007/s00520-014-2248-6. Epub 2014 May 17.

PMID:
24838259
30.

Circulating miRNA markers show promise as new prognosticators for multiple myeloma.

Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F.

Leukemia. 2014 Sep;28(9):1922-6. doi: 10.1038/leu.2014.155. Epub 2014 May 12. No abstract available.

31.

Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.

Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Kwon CH, Wang QE, Devine SM, He X, Bai XF, Hofmeister CC, Yu J.

Clin Cancer Res. 2014 Aug 1;20(15):3989-4000. doi: 10.1158/1078-0432.CCR-13-2510. Epub 2014 Mar 27.

32.

Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred.

Efebera YA, Sturm A, Baack EC, Hofmeister CC, Satoskar A, Nadasdy T, Nadasdy G, Benson DM, Gillmore JD, Hawkins PN, Rowczenio D.

Amyloid. 2014 Jun;21(2):110-2. doi: 10.3109/13506129.2014.891502. Epub 2014 Mar 6.

33.

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC.

Blood. 2014 Mar 20;123(12):1826-32. doi: 10.1182/blood-2013-11-538835. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9.

34.

FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.

He S, Chu J, Vasu S, Deng Y, Yuan S, Zhang J, Fan Z, Hofmeister CC, He X, Marsh HC, Devine SM, Yu J.

Biol Blood Marrow Transplant. 2014 Mar;20(3):309-13. doi: 10.1016/j.bbmt.2013.11.024. Epub 2013 Dec 21.

35.

A phase I trial of flavopiridol in relapsed multiple myeloma.

Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC.

Cancer Chemother Pharmacol. 2014 Feb;73(2):249-57. doi: 10.1007/s00280-013-2347-y. Epub 2013 Nov 16.

36.

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM Jr.

Cancer Immunol Immunother. 2013 Dec;62(12):1841-9. doi: 10.1007/s00262-013-1493-8. Epub 2013 Oct 26.

37.

Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.

Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MA.

J Pharm Biomed Anal. 2014 Jan;88:262-8. doi: 10.1016/j.jpba.2013.08.036. Epub 2013 Sep 2.

38.

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.

Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J.

Leukemia. 2014 Apr;28(4):917-27. doi: 10.1038/leu.2013.279. Epub 2013 Sep 26.

39.

Characterization of multiple myeloma vesicles by label-free relative quantitation.

Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F.

Proteomics. 2013 Oct;13(20):3013-29. doi: 10.1002/pmic.201300142.

40.

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM.

J Exp Med. 2013 May 6;210(5):951-68. doi: 10.1084/jem.20120950. Epub 2013 Apr 22. Erratum in: J Exp Med. 2017 May 1;214(5):1557.

41.

Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.

Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA.

Clin Pharmacokinet. 2013 Aug;52(8):705-12. doi: 10.1007/s40262-013-0064-7.

42.

MicroRNAs activate natural killer cells through Toll-like receptor signaling.

He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM Jr, Hofmeister CC, He X, Ghoshal K, Devine SM, Caligiuri MA, Yu J.

Blood. 2013 Jun 6;121(23):4663-71. doi: 10.1182/blood-2012-07-441360. Epub 2013 Apr 11.

43.

Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.

Clark JI, Greene JB, Lau Clark A, Dalal JS, Hofmeister CC.

Med Oncol. 2013 Mar;30(1):358. doi: 10.1007/s12032-012-0358-x. Epub 2012 Dec 25.

PMID:
23266940
44.

Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.

Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA.

Leuk Lymphoma. 2013 Aug;54(8):1658-64. doi: 10.3109/10428194.2012.751528. Epub 2012 Dec 31.

45.

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS.

Blood. 2012 Nov 22;120(22):4324-33. doi: 10.1182/blood-2012-06-438028. Epub 2012 Oct 1.

46.

Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.

Bruce JT, Tran JM, Phillips G, Elder P, Mastronarde JG, Devine SM, Hofmeister CC, Wood KL.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):325-9. doi: 10.1016/j.clml.2012.06.002. Epub 2012 Sep 15.

47.

Unique pattern of renal κ light chain amyloid deposition with histiocytic transdifferentiation of tubular epithelial cells.

Hemminger J, Satoskar A, Brodsky SV, Calomeni E, Nadasdy GM, Kovach P, Hofmeister CC, Nadasdy T.

Am J Surg Pathol. 2012 Aug;36(8):1253-7. doi: 10.1097/PAS.0b013e31825b845e.

PMID:
22790864
48.

Lenalidomide after stem-cell transplantation for multiple myeloma.

McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C.

N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.

49.

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS.

Blood. 2011 Dec 8;118(24):6387-91. doi: 10.1182/blood-2011-06-360255. Epub 2011 Oct 26.

50.

Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.

Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM Jr.

Hematol Oncol. 2012 Sep;30(3):156-62. doi: 10.1002/hon.1019. Epub 2011 Oct 26.

Supplemental Content

Loading ...
Support Center